Protara Therapeutics, Inc. (TARA)
NASDAQ:TARA
Want to see TARA full AI Analyst Report?
Top Page
Protara Therapeutics
(NASDAQ:TARA)
Select Model
Select Model
Rating:48Neutral
Price Target:
$5.50
▲(1.10% Upside)
Action:ReiteratedDate:03/30/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn) and bearish technical momentum (below key moving averages with negative MACD). Offsetting factors include a comparatively low-debt balance sheet and positive Phase 2 TARA-002 clinical results that improve the company’s outlook and potential funding flexibility.
Positive Factors
Positive Phase 2 TARA-002 data
Durable clinical efficacy well above the 41.9% benchmark and a favorable safety profile materially strengthen the registrational case for TARA-002. This raises the likelihood of approval, partner interest, and long-term commercial potential, improving strategic optionality over the next several months.
Negative Factors
No revenue and recurring losses
As a pre-commercial biotech with no product sales, the company depends on external financing to operate. Persistent net losses drive negative returns on equity and create an ongoing need for capital, structurally increasing dilution risk until commercialization or material partnership revenue emerges.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive Phase 2 TARA-002 data
Durable clinical efficacy well above the 41.9% benchmark and a favorable safety profile materially strengthen the registrational case for TARA-002. This raises the likelihood of approval, partner interest, and long-term commercial potential, improving strategic optionality over the next several months.
Read all positive factors
Protara Therapeutics (TARA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$281.78M
Dividend YieldN/A
Average Volume (3M)745.65K
Price to Earnings (P/E)―
Beta (1Y)0.83
Revenue GrowthN/A
EPS Growth48.84%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.37
Shares Outstanding54,084,377
10 Day Avg. Volume450,507
30 Day Avg. Volume745,650
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-4.04
Enterprise Value/Market Cap0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-904.02
Enterprise Value/Ebitda-2.67
Forecast
1Y Price Target
$26.00Price Target Upside377.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.51
Revenue Forecast (FY)N/A
Protara Therapeutics Business Overview & Revenue Model
Company Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cel...
How the Company Makes Money
null...
Protara Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
66
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -362.00K | 0.00 | -341.00K | 0.00 | 0.00 |
| EBITDA | -64.19M | -48.82M | -43.27M | -64.57M | -45.40M |
| Net Income | -57.44M | -44.60M | -40.42M | -65.95M | -47.25M |
Balance Sheet | |||||
| Total Assets | 209.47M | 181.45M | 78.95M | 113.29M | 172.60M |
| Cash, Cash Equivalents and Short-Term Investments | 155.55M | 170.29M | 65.58M | 84.37M | 91.23M |
| Total Debt | 3.36M | 4.48M | 5.47M | 6.38M | 7.24M |
| Total Liabilities | 13.06M | 14.32M | 10.63M | 11.21M | 10.68M |
| Stockholders Equity | 196.41M | 167.13M | 68.32M | 102.08M | 161.91M |
Cash Flow | |||||
| Free Cash Flow | -56.46M | -35.87M | -37.60M | -26.58M | -35.10M |
| Operating Cash Flow | -56.37M | -35.81M | -37.56M | -26.46M | -34.50M |
| Investing Cash Flow | -139.49M | 19.16M | 53.11M | 14.95M | -98.19M |
| Financing Cash Flow | 82.72M | 139.87M | -91.00K | -90.00K | -228.00K |
Protara Therapeutics Technical Analysis
Positive
5.44
Price Trends
5.71
Negative
5.85
Negative
4.92
Positive
Market Momentum
-0.11
Negative
53.10
Neutral
63.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TARA, the sentiment is Positive. The current price of 5.44 is above the 20-day moving average (MA) of 5.14, below the 50-day MA of 5.71, and above the 200-day MA of 4.92, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 53.10 is Neutral, neither overbought nor oversold. The STOCH value of 63.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TARA.
Protara Therapeutics Risk Analysis
Protara Therapeutics disclosed 62 risk factors in its most recent earnings report. Protara Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Protara Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $191.76M | -21.41 | -13.46% | ― | 35.42% | ― | |
52 Neutral | $267.44M | -3,008.78 | -169.64% | ― | 6.46% | -14.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $539.87M | -4.97 | -83.86% | ― | ― | -19.69% | |
48 Neutral | $281.78M | -3.97 | -36.38% | ― | ― | 48.84% | |
48 Neutral | $195.19M | -1.21 | -179.42% | ― | ― | 99.21% | |
44 Neutral | $25.80M | -0.51 | -143.59% | ― | ― | -53.18% |
* Healthcare Sector Average
TARA
Protara Therapeutics
5.44
1.59
41.30%
PLX
Protalix
2.32
-0.23
-9.02%
HURA
TuHURA Biosciences
2.92
-1.28
-30.48%
SKYE
Skye Bioscience
0.79
-0.78
-49.81%
OBIO
Orchestra BioMed Holdings
4.58
1.74
61.27%
ZURA
Zura Bio
5.81
4.44
324.09%
Protara Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results
Positive
Mar 30, 2026
On March 30, 2026, Protara Therapeutics reported updated data from its ongoing Phase 2 ADVANCED-2 trial of TARA-002 in Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, confirming a six-month complete response rate of ...
Business Operations and StrategyProduct-Related Announcements
Protara Highlights Strong Phase 2 Data for TARA-002
Positive
Feb 24, 2026
On February 23, 2026, Protara Therapeutics reported updated interim results from its ongoing Phase 2 open-label ADVANCED-2 trial of intravesical TARA-002 in high-risk non-muscle invasive bladder cancer with carcinoma in situ in patients who are BC...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.